NO309227B3 - Anvendelse av 5-[2-etoksy-5-(4-metyl-1-piperazinylsulfonyl)fenyl]-1-metyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-on for fremstilling av et medikament for behandling av erektil dysfunksjon - Google Patents

Anvendelse av 5-[2-etoksy-5-(4-metyl-1-piperazinylsulfonyl)fenyl]-1-metyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-on for fremstilling av et medikament for behandling av erektil dysfunksjon Download PDF

Info

Publication number
NO309227B3
NO309227B3 NO19954757A NO954757A NO309227B3 NO 309227 B3 NO309227 B3 NO 309227B3 NO 19954757 A NO19954757 A NO 19954757A NO 954757 A NO954757 A NO 954757A NO 309227 B3 NO309227 B3 NO 309227B3
Authority
NO
Norway
Prior art keywords
methyl
alkyl
treatment
erectile dysfunction
optionally substituted
Prior art date
Application number
NO19954757A
Other languages
English (en)
Norwegian (no)
Other versions
NO954757D0 (no
NO309227B1 (no
NO954757L (no
Inventor
Peter Ellis
Nicholas Kenneth Terret
Original Assignee
Pfizer Ireland Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10736901&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO309227(B3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Ireland Pharmaceuticals filed Critical Pfizer Ireland Pharmaceuticals
Publication of NO954757D0 publication Critical patent/NO954757D0/no
Publication of NO954757L publication Critical patent/NO954757L/no
Publication of NO309227B1 publication Critical patent/NO309227B1/no
Publication of NO309227B3 publication Critical patent/NO309227B3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Paper (AREA)
  • Hydroponics (AREA)
NO19954757A 1993-06-09 1995-11-24 Anvendelse av 5-[2-etoksy-5-(4-metyl-1-piperazinylsulfonyl)fenyl]-1-metyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-on for fremstilling av et medikament for behandling av erektil dysfunksjon NO309227B3 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939311920A GB9311920D0 (en) 1993-06-09 1993-06-09 Therapeutic agents
PCT/EP1994/001580 WO1994028902A1 (en) 1993-06-09 1994-05-13 Pyrazolopyrimidinones for the treatment of impotence

Publications (4)

Publication Number Publication Date
NO954757D0 NO954757D0 (no) 1995-11-24
NO954757L NO954757L (no) 1995-11-24
NO309227B1 NO309227B1 (no) 2001-01-02
NO309227B3 true NO309227B3 (no) 2011-02-21

Family

ID=10736901

Family Applications (3)

Application Number Title Priority Date Filing Date
NO19954757A NO309227B3 (no) 1993-06-09 1995-11-24 Anvendelse av 5-[2-etoksy-5-(4-metyl-1-piperazinylsulfonyl)fenyl]-1-metyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-on for fremstilling av et medikament for behandling av erektil dysfunksjon
NO20000702A NO325558B1 (no) 1993-06-09 2000-02-11 Anvendelse av cGMP PDEv-inhibitorer for fremstilling av medikamenter til behandling av erektil dysfunksjon.
NO20000703A NO321622B1 (no) 1993-06-09 2000-02-11 Pyrazolopyridmidioner for behandling av kvinnelig seksuell dysfunksjon

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20000702A NO325558B1 (no) 1993-06-09 2000-02-11 Anvendelse av cGMP PDEv-inhibitorer for fremstilling av medikamenter til behandling av erektil dysfunksjon.
NO20000703A NO321622B1 (no) 1993-06-09 2000-02-11 Pyrazolopyridmidioner for behandling av kvinnelig seksuell dysfunksjon

Country Status (28)

Country Link
US (2) US6469012B1 (ru)
EP (1) EP0702555B1 (ru)
JP (4) JP2925034B2 (ru)
KR (2) KR100262926B1 (ru)
CN (2) CN1071118C (ru)
AT (1) ATE163852T1 (ru)
AU (1) AU676571C (ru)
CA (1) CA2163446C (ru)
CY (1) CY2099B1 (ru)
CZ (1) CZ284946B6 (ru)
DE (1) DE69408981T2 (ru)
DK (1) DK0702555T3 (ru)
EC (1) ECSP941102A (ru)
ES (1) ES2113656T3 (ru)
FI (1) FI955911A0 (ru)
GB (2) GB9301192D0 (ru)
GR (1) GR3026520T3 (ru)
HU (1) HU227877B1 (ru)
IL (3) IL121836A (ru)
LV (1) LV12269B (ru)
MY (1) MY111446A (ru)
NO (3) NO309227B3 (ru)
NZ (2) NZ266463A (ru)
PL (1) PL311948A1 (ru)
RU (1) RU2373938C9 (ru)
TW (1) TW292971B (ru)
WO (1) WO1994028902A1 (ru)
ZA (1) ZA944018B (ru)

Families Citing this family (239)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060222647A1 (en) * 1993-05-27 2006-10-05 Beavo Joseph A Methods and compositions for modulating the activity of PDE5
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
GB9514465D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9423911D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
SK154498A3 (en) * 1996-05-10 2000-01-18 Icos Corp Carboline derivatives, process for the preparation thereof, pharmaceutical compositions containing same and use of mentioned derivatives as drugs
GB9612514D0 (en) * 1996-06-14 1996-08-14 Pfizer Ltd Novel process
DE19642284A1 (de) * 1996-10-14 1998-04-16 Merck Patent Gmbh Pyrazolinone zur Behandlung von Potenzstörungen
KR100390612B1 (ko) * 1997-04-25 2003-07-07 화이자 인코포레이티드 타입 5 시클릭 구아노신 3',5'-모노포스페이트포스포디에스테라제를 억제하는 성기능 장애 치료용피라졸로피리미디논 제조용 중간체의 제조 방법
IL132993A0 (en) * 1997-05-29 2001-03-19 Mochida Pharm Co Ltd Therapeutic agent for erection failure
JP2001509480A (ja) 1997-07-09 2001-07-24 アンドロソリューションズ，インク． 男性勃起機能不全を治療するための改良された方法及び組成物
US20020025969A1 (en) * 1997-07-09 2002-02-28 Wolf-Georg Forssmann Use of phosphordiesterase inhibitors in the treatment of prostatic diseases
US6399618B1 (en) 1997-07-09 2002-06-04 Cardiome Pharma Corp Compositions and methods for modulating sexual activity
US6103765A (en) 1997-07-09 2000-08-15 Androsolutions, Inc. Methods for treating male erectile dysfunction
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US6593369B2 (en) 1997-10-20 2003-07-15 Vivus, Inc. Methods, compositions, and kits for enhancing female sexual desire and responsiveness
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
EP1027057A4 (en) 1997-10-28 2003-01-02 Vivus Inc TREATMENT OF FEMALE SEXUAL DISORDERS
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
EP1027054A4 (en) * 1997-10-28 2002-11-04 Vivus Inc LOCAL CONTRIBUTION OF PHOSPHODIESTERASE INHIBITORS IN THE TREATMENT OF ERECTILE DYSFUNCTION
US6127363A (en) * 1997-10-28 2000-10-03 Vivus, Inc. Local administration of Type IV phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6156753A (en) * 1997-10-28 2000-12-05 Vivus, Inc. Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction
ATE213246T1 (de) * 1997-11-12 2002-02-15 2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren
DE19752952A1 (de) 1997-11-28 1999-06-02 Merck Patent Gmbh Thienopyrimidine
CN1282248A (zh) * 1997-12-16 2001-01-31 辉瑞产品公司 阳萎的联合治疗
TW542719B (en) * 1998-02-23 2003-07-21 Pfizer Res & Dev Method of treating impotence due to spinal cord injury
ATE247117T1 (de) * 1998-04-20 2003-08-15 Pfizer Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen
DE19819023A1 (de) 1998-04-29 1999-11-04 Merck Patent Gmbh Thienopyrimidine
US6132753A (en) * 1998-05-01 2000-10-17 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
US6194433B1 (en) 1998-10-05 2001-02-27 Neal R. Cutler Sexual dysfunction in females
US6110489A (en) * 1998-05-01 2000-08-29 Cutler; Neal R. Use of quinolines and quinolones to treat male erectile dysfunction
US6187790B1 (en) 1999-03-04 2001-02-13 Neal R. Cutler Use of cilostazol for treatment of sexual dysfunction
US6132757A (en) * 1998-05-01 2000-10-17 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
US6541487B1 (en) 1998-05-01 2003-04-01 R.T. Alamo Ventures I, Llc PDE III inhibitors for treating sexual dysfunction
CA2319542C (en) * 1998-05-01 2005-07-12 Rt Alamo Ventures, Inc. The treatment of sexual dysfunction in certain patient groups
US6426084B1 (en) 2000-06-19 2002-07-30 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
AU4068599A (en) * 1998-05-20 1999-12-06 Schering Corporation Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
EP0967284A1 (en) * 1998-05-28 1999-12-29 Pfizer Limited Phosphodiesterases
TWI223598B (en) * 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
JP2002518417A (ja) 1998-06-25 2002-06-25 ラヴィファム ラボラトリーズ インコーポレーテッド 勃起機能不全の治療装具及び方法
US7087240B1 (en) 1998-06-25 2006-08-08 Lavipharm Laboratories Inc. Device and method for the treatment of erectile dysfunction
WO2000000199A1 (en) * 1998-06-26 2000-01-06 Nastech Pharmaceutical Company, Inc. Nasal delivery of sildenafil citrate
DE19837067A1 (de) 1998-08-17 2000-02-24 Bayer Ag Verfahren zur Herstellung von 1-Alkyl-pyrazol-5-carbonsäureestern
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
ATE264861T1 (de) * 1998-09-04 2004-05-15 Ortho Mcneil Pharm Inc 5-heterozyklyl-pyrazolo(4,3-d)pyrimidin-7-one für die behandlung von männlichen erectilen dysfunktionen
WO2000020033A1 (fr) 1998-10-05 2000-04-13 Eisai Co., Ltd. Comprimes se delitant immediatement dans la cavite buccale
JP2000178204A (ja) * 1998-10-05 2000-06-27 Eisai Co Ltd ホスフォジエステラ―ゼ阻害剤を含有する口腔内速崩壊性錠剤
JP2000191518A (ja) * 1998-10-19 2000-07-11 Eisai Co Ltd 溶解性の改善された口腔内速崩壊性錠剤
UA67802C2 (ru) 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ПЕРОРАЛЬНОГО ПРИМЕНЕНИЯ С КОНТРОЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ ИНГИБИТОРА цГМФ ФДЭ-5 (ВАРИАНТЫ), СПОСОБ ЕЕ ПОЛУЧЕНИЯ И СПОСОБ ЛЕЧЕНИЯ ЭРЕКТИЛЬНОЙ ДИСФУНКЦИИ
GB9823103D0 (en) * 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823102D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823101D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
KR100353014B1 (ko) * 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
US6225315B1 (en) 1998-11-30 2001-05-01 Pfizer Inc Method of treating nitrate-induced tolerance
GB9828340D0 (en) * 1998-12-22 1999-02-17 Novartis Ag Organic compounds
US6455564B1 (en) 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
WO2000043012A1 (en) * 1999-01-22 2000-07-27 Selectus Pharmaceuticals, Inc. Controlling heart rate or blood pressure in patients co-medicated with phosphodiesterase inhibitors for treatment of impotence
WO2000053148A2 (en) * 1999-03-08 2000-09-14 Merck & Co., Inc. Methods and compositions for treating erectile dysfunction
JP2002540102A (ja) 1999-03-22 2002-11-26 ブリストル−マイヤーズ スクイブ カンパニー ｃＧＭＰホスホジエステラーゼの縮合ピリドピリダジン阻害剤
US6214849B1 (en) 1999-04-29 2001-04-10 Lupin Laboratories Limited Use of nicorandil in treatment of sexual dysfunction or for enhancement of sexual function in mammals including humans
MXPA00003997A (es) * 1999-04-30 2002-03-08 Lilly Icos Llc Articulos de fabricacion.
US6451807B1 (en) * 1999-04-30 2002-09-17 Lilly Icos, Llc. Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
US7258850B2 (en) * 1999-05-04 2007-08-21 Aradigm Corporation Methods and compositions for treating erectile dysfunction
JP3145364B2 (ja) 1999-06-04 2001-03-12 ザ・ヨルダニアン・フアーマシユーテイカル・エム・エフ・ジー・アンド・メデイカル・イクイツプメント・カンパニー・リミテツド 新規化合物及び該化合物を含有する医薬組成物
WO2000078760A1 (fr) * 1999-06-21 2000-12-28 The Biochemical Pharmaceutical Factory Of Zhuhai Sez Procede de preparation de sildenafil, agent et procede d'obtention d'un comprime mixte a base de sildenafil et de chlorhydrate d'apomorphine
US6303135B1 (en) 1999-07-08 2001-10-16 Neal R. Cutler Use of quinolines and quinolones to treat male erectile dysfunction
CN1077108C (zh) * 1999-07-13 2002-01-02 成都地奥制药集团有限公司 用于制备药物昔多芬的前体化合物
IL130968A (en) 1999-07-15 2002-12-01 Shmuel Simon Pharmaceutical composition comprising sildenafil or its analogs, useful for the treatment of tinnitus and hearing loss
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
DE19944161A1 (de) * 1999-09-15 2001-03-22 Bayer Ag Neue Kombination zur Behandlung von sexueller Dysfunktion
HU225917B1 (en) 1999-09-16 2007-12-28 Tanabe Seiyaku Co Pyrimidine and pyrazine derivatives, pharmaceutical compositions containing them and their use
US6436944B1 (en) 1999-09-30 2002-08-20 Pfizer Inc. Combination effective for the treatment of impotence
BR0014695A (pt) 1999-10-11 2002-06-18 Pfizer 5-(2-substituìdo-5-heterociclilsulfonilpirid-3-il)-dihi dropirazolo[4,3-d]pirimidin-7-onas como inibidoras de fosfodiesterase
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
US20040254153A1 (en) * 1999-11-08 2004-12-16 Pfizer Inc Compounds for the treatment of female sexual dysfunction
IL150022A0 (en) 1999-12-24 2002-12-01 Bayer Ag Imidazo [1,3,5] triazinones and the use thereof
KR100358083B1 (ko) * 2000-02-17 2002-10-25 에스케이케미칼주식회사 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도
DE10010067A1 (de) 2000-03-02 2001-09-06 Bayer Ag Neue Imidazotriazinone und ihre Verwendung
GB0008694D0 (en) * 2000-04-07 2000-05-31 Novartis Ag Organic compounds
US7019136B2 (en) 2000-04-07 2006-03-28 Novartis, Ag 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors
DE10017947A1 (de) * 2000-04-11 2001-10-25 Merck Patent Gmbh Verfahren zur Herstellung benzo-annelierter Heterocyclen
US7273868B2 (en) 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
MXPA02010693A (es) 2000-04-28 2003-03-10 Tanabe Seiyaku Co Compuestos ciclicos.
AU2000254308A1 (en) * 2000-05-17 2001-11-26 Sk Chemicals Co., Ltd. Pyrazolopyrimidinone derivatives, process for their preparation and their use
UA74826C2 (en) 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
UA72611C2 (ru) * 2000-05-17 2005-03-15 Орто-Макнейл Фармацевтикал, Інк. Translated By PlajПРОИЗВОДНЫЕ ЗАМЕЩЕННОГО ПИРОЛОПИРИДИНОНА, ПОЛЕЗНЫЕ КАК ИНГИБИТОРЫ ФОСФОДИЭСТЕРАЗЫ
US6667398B2 (en) 2000-06-22 2003-12-23 Pfizer Inc Process for the preparation of pyrazolopyrimidinones
US6730786B2 (en) * 2000-06-22 2004-05-04 Pfizer Inc Process for the preparation of pyrazolopyrimidinones
DE10031584A1 (de) 2000-06-29 2002-01-10 Merck Patent Gmbh 5-Aminoalkyl-pyrazolo[4,3-d]pyrimidine
DE10031585A1 (de) 2000-06-29 2002-01-10 Merck Patent Gmbh 2-Aminoalkyl-thieno[2,3-d]pyrimidine
WO2002003993A2 (en) * 2000-07-12 2002-01-17 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Use of inhibitors to multidrug resistance protein 5 (mrp5) to enhance intracellular levels of cyclic nucleotides
BRPI0003386B8 (pt) * 2000-08-08 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda pró-droga homo ou heterodiméricas úteis no tratamento de doenças ou disfunções mediadas por fosfodiesterases; composições farmacêuticas contendo a pró-droga ou seus sais farmacêuticos aceitáveis; processo de obtenção destas pró-drogas
PE20020394A1 (es) 2000-08-18 2002-06-21 Agouron Pharma Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2
AU2000267375A1 (en) * 2000-08-23 2002-03-04 Lg Life Sciences Ltd. Polyethoxylated pyrazolo pyrimidinone derivatives, process for preparation thereof and pharmaceutical compositions comprising the same for the treatment of impotence
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
WO2002020058A1 (fr) 2000-09-06 2002-03-14 Tanabe Seiyaku Co., Ltd. Preparations administrees par voie orale
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
GB0025782D0 (en) * 2000-10-20 2000-12-06 Pfizer Ltd Use of inhibitors
DE60005024T2 (de) * 2000-10-23 2004-06-24 The Jordanian Pharmaceutical Manufacturing and Medical Equipment Co. Ltd. Verwendung von Sulfadiazin und Sulfadimidine zur Behandlung der erektilen Dysfunktion
DE10063108A1 (de) * 2000-12-18 2002-06-20 Bayer Ag Verfahren zur Herstellung von Sulfonamid-substituierten Imidazotriazinonen
SE0004780D0 (sv) 2000-12-22 2000-12-22 Jordanian Pharmaceutical Mfg & Novel compunds
JP3940290B2 (ja) * 2000-12-22 2007-07-04 ザ・ヨルダニアン・フアーマシユーテイカル・エム・エフ・ジー・アンド・メデイカル・イクイツプメント・カンパニー・リミテツド 新規化合物
CA2437085A1 (en) * 2001-02-02 2002-08-15 Merck Patent Gesellschaft Mit Beschraenkter Haftung Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists
ATE472319T1 (de) 2001-02-15 2010-07-15 Mitsubishi Tanabe Pharma Corp Tabletten, die in der mundhöhle schnell zerfallen
DE10107639A1 (de) * 2001-02-15 2002-08-22 Bayer Ag 2-Alkoxyphenyl-substituierte Imidazotriazinone
WO2002068419A1 (fr) 2001-02-26 2002-09-06 Tanabe Seiyaku Co., Ltd. Derive de pyridopyrimidine ou naphthyridine
US6784185B2 (en) 2001-03-16 2004-08-31 Pfizer Inc. Pharmaceutically active compounds
MXPA03006310A (es) * 2001-03-16 2003-09-16 Pfizer Compuestos farmaceuticamente activos.
US20050164220A1 (en) * 2001-03-19 2005-07-28 Decode Genetics Ehf. Susceptibility gene for human stroke: method of treatment
WO2004028341A2 (en) * 2001-03-19 2004-04-08 Decode Genetics Ehf. Susceptibility gene for human stroke; methods of treatment
US20030054531A1 (en) * 2001-03-19 2003-03-20 Decode Genetics Ehf, Human stroke gene
US20040014099A1 (en) * 2001-03-19 2004-01-22 Decode Genetics Ehf. Susceptibility gene for human stroke; methods of treatment
US6794387B2 (en) 2001-03-28 2004-09-21 Pfizer Inc. Pharmaceutically active compounds
GB0107751D0 (en) * 2001-03-28 2001-05-16 Pfizer Ltd Pharmaceutically active compounds
DE10118306A1 (de) 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
WO2002083631A1 (en) 2001-04-13 2002-10-24 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
EP1404336A1 (en) * 2001-06-14 2004-04-07 Sampad Bhattacharya Compositions comprising cgmppde5 inhibitor for transdermal delivery to the erectile tissue of the penis
KR100393160B1 (ko) * 2001-06-14 2003-07-31 한국과학기술연구원 신규한 피라졸로피리미딘티온 유도체, 그의 제법 및발기부전 치료제로서의 용도
CN1127506C (zh) * 2001-06-29 2003-11-12 刘宝顺 一种治疗阳痿的新化合物
DE10135815A1 (de) 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
ES2302835T3 (es) 2001-08-28 2008-08-01 Schering Corporation Inhibidores de fosfodiesterasa v policiclicos de guanina.
EP1790652A1 (en) * 2001-08-28 2007-05-30 Schering Corporation Polycyclic guanine phosphodiesterase V inhibitors
US20030087963A1 (en) 2001-09-13 2003-05-08 Senanayake Chris H. Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
WO2003042216A1 (en) * 2001-11-09 2003-05-22 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
CA2439784C (en) * 2001-12-13 2010-11-02 Daiichi Suntory Pharma Co., Ltd. Pyrazolopyrimidinone derivatives having pde7 inhibiting action
US7645878B2 (en) 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
AU2003249658A1 (en) * 2002-05-31 2003-12-19 Schering Corporation Xanthine phosphodiesterase v inhibitor polymorphs
EP1719772A1 (en) 2002-05-31 2006-11-08 Schering Corporation Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
DE60317684T4 (de) 2002-06-19 2011-06-22 Janssen Pharmaceutica N.V., 2340 SUBSTITUIERTE 2,4-DIHYDROPYRROLOc3,4BÜCHINOLIN-9-ONDERIVATE, DIE SICH ALS PHOSPHODIESTERASEINHIBITOREN EIGNEN
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
WO2004072079A1 (en) * 2003-02-11 2004-08-26 Pfizer Limited Hydrated and anhydrous sildenafil hemi-citrate compound
CN100374441C (zh) 2003-06-06 2008-03-12 天津倍方科技发展有限公司 二氢吡咯[2，3-d]嘧啶-4-酮衍生物，其制备方法及其制药用途
DE10325813B4 (de) 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
EP3342420A1 (en) * 2003-06-13 2018-07-04 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
US20070287937A1 (en) * 2003-12-02 2007-12-13 Hakuju Institute For Health Services Nonpharmacological Generative Function Control Method and Its Apparatus
CN100360531C (zh) * 2003-12-18 2008-01-09 中国人民解放军军事医学科学院放射与辐射医学研究所 用于预防或治疗阳萎和性冷淡的新吡唑并嘧啶类化合物
CA2563678A1 (en) * 2004-04-19 2005-11-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
PT1750766E (pt) 2004-05-11 2013-09-30 Emotional Brain Bv Formulações farmacêuticas e suas utilizações no tratamento de disfunção sexual feminina
US7700608B2 (en) 2004-08-04 2010-04-20 Shire Holdings Ag Quinazoline derivatives and their use in the treatment of thrombocythemia
US20060030574A1 (en) 2004-08-04 2006-02-09 Shire Holdings Ag Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors
BRPI0514410A (pt) * 2004-08-23 2008-06-10 Mannkind Corp fornecimento pulmonar de inibidores de fosfodiesterase do tipo 5
CN100347174C (zh) * 2004-09-10 2007-11-07 上海特化医药科技有限公司 杂环并嘧啶酮衍生物、制备方法和用途
EA011391B1 (ru) 2004-10-18 2009-02-27 Полимун Сайнтифик Иммунбиологише Форшунг Гмбх Липосомная композиция, содержащая активное вещество для релаксации гладкой мускулатуры, получение этой композиции и ее терапевтическое применение
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
US20060235005A1 (en) * 2005-04-14 2006-10-19 Oak Labs, Corp. Use of phosphodiesterase 5 (PDE5) inhibitors in the treatment of schizophrenia
UA84688C2 (ru) * 2005-04-15 2008-11-25 Виктор Павлович Кутняк Средство для лечения эректильной дисфункции
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
AU2006311577B2 (en) 2005-11-09 2013-02-07 Zalicus Inc. Methods, compositions, and kits for the treatment of medical conditions
EP1790343A1 (en) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
CN1966506A (zh) 2005-11-17 2007-05-23 上海特化医药科技有限公司 吡唑并嘧啶酮衍生物及其制备方法和用途
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007124045A2 (en) * 2006-04-20 2007-11-01 Ampla Pharmaceuticals, Inc. Piperidine and piperazine compounds for use in the treatment of obesity, eating disorders and sexual dysfunction by potentiation of mc4 receptor activity
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
JP5797376B2 (ja) * 2006-05-15 2015-10-21 ユナイテッド セラピューティクス コーポレーション 定量吸入器を用いたトレプロスチニル投与
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP1925307A1 (en) 2006-11-03 2008-05-28 Emotional Brain B.V. Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
US7910597B2 (en) 2006-11-28 2011-03-22 Shire Llc Substituted quinazolines
US8071765B2 (en) 2006-12-21 2011-12-06 Topharman Shanghai Co., Ltd. Process for the preparation of sildenafil and intermediates thereof
US20080194529A1 (en) * 2007-02-12 2008-08-14 Auspex Pharmaceuticals, Inc. HIGHLY SELECTIVE and LONG-ACTING PDE5 MODULATORS
CA2677690C (en) * 2007-02-12 2012-05-15 James V. Winkler Treatment of comorbid premature ejaculation and erectile dysfunction
WO2008100933A2 (en) 2007-02-12 2008-08-21 Dmi Biosciences, Inc. Reducing side effects of tramadol
ES2310144B1 (es) 2007-06-15 2010-01-12 Galenicum Health, S.L. Intermedios para la preparacion de un inhibidor de la fosfodiesterasa tipo 5.
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
US20090181975A1 (en) * 2008-01-15 2009-07-16 Forest Laboratories Holdings Limited Nebivolol in the treatment of sexual dysfunction
SI2296633T1 (sl) 2008-05-02 2015-11-30 Gilead Sciences, Inc. Uporaba trdnih nosilnih delcev za izboljšanje predelovalnih sposobnosti farmacevtskega sredstva
EP2305237B1 (en) * 2008-05-14 2014-04-30 SBI Pharmaceuticals Co., Ltd. Therapeutic agent for male sterility
CN101747282A (zh) 2008-12-10 2010-06-23 上海特化医药科技有限公司 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途
EP2374460A4 (en) * 2008-12-12 2013-08-21 Rhein Siegfried Sa De Cv SILDENAFIL COMPOSITION WITH PULSED RELEASE AND METHOD FOR PRODUCING THIS COMPOSITION
DE102008063992A1 (de) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
WO2010070617A1 (en) 2008-12-19 2010-06-24 Shimoda Biotech (Pty) Ltd Inclusion complexes of alpha-cyclodextrin and sildenafil salt
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20100261737A1 (en) * 2009-04-10 2010-10-14 Medtronic Vascular, Inc. Method of Treating Erectile Dysfunction
WO2010146407A1 (en) 2009-06-19 2010-12-23 Nanoform Hungary Ltd. Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
DE102009033396A1 (de) 2009-07-16 2011-01-20 Ratiopharm Gmbh Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
DE102009035211A1 (de) 2009-07-29 2011-02-17 Ratiopharm Gmbh Copräzipitate umfassend einen Phosphodiesterase-5-Inhibitor (PDE-5-Inhibitor) und einen pharmazeutisch verträglichen Trägerstoff, ihre Herstellung und Verwendung
WO2011051928A1 (en) 2009-10-30 2011-05-05 Medispec Ltd Method and apparatus for treatment of erectile dysfunction with extracorporeal shockwaves
PT2504334E (pt) 2009-11-27 2014-12-03 Bayer Ip Gmbh Processo para a purificação de metil-{4,6-diamino-2-[1-(2- fluorobenzil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5- il}metilcarbamato
UY33041A (es) 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
JP5806231B2 (ja) 2009-12-21 2015-11-10 アセフ エス．アー． 勃起障害の治療における血管拡張剤としてのクベビン、ジベンジルブチルロラクトリンリグナン、その半合成誘導体および合成誘導体、ならびに他のリグナンおよびネオリグナン
MA34019B1 (fr) 2010-02-27 2013-02-01 Bayer Ip Gmbh Aryltriazolone liée à un bis-aryle et son utilisation
ES2611187T3 (es) 2010-03-15 2017-05-05 United Therapeutics Corporation Tratamiento para hipertensión pulmonar
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
WO2012000634A1 (de) 2010-06-29 2012-01-05 Georg Bambach Pharmazeutische zusammensetzung zur behandlung von erektiler dysfunktion
CN101891747B (zh) * 2010-07-02 2012-04-25 张南 抑制5型磷酸二酯酶的化合物及制备方法
TW201210584A (en) 2010-08-18 2012-03-16 Alcon Res Ltd Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma
DE102010040187A1 (de) 2010-09-02 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Substituierte N-Phenethyl-triazolonacetamide und ihre Verwendung
DE102010040924A1 (de) 2010-09-16 2012-03-22 Bayer Schering Pharma Aktiengesellschaft Substituierte Phenylacet- und Phenylpropanamide und ihre Verwendung
CN105920603B (zh) 2010-12-29 2022-02-11 战略科学与技术有限责任公司 勃起功能障碍和其它适应症的治疗
ME02200B (me) 2011-02-02 2016-02-20 Novartis Ag Postupci za korisćenje alk inhibitora
JP6158801B2 (ja) 2011-07-15 2017-07-05 ニューサート サイエンシーズ， インコーポレイテッド 代謝経路を変調させるための組成物および方法
AT512084A1 (de) 2011-10-20 2013-05-15 Univ Wien Tech Diazabicyclo- und diazaspiro-alkanderivate als phosphodiesterase-5 inhibitoren
WO2013067309A1 (en) 2011-11-04 2013-05-10 Xion Pharmaceutical Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
JP5941558B2 (ja) 2012-02-28 2016-06-29 株式会社ソウル製薬Ｓｅｏｕｌ Ｐｈａｒｍａ． Ｃｏ．， Ｌｔｄ． シルデナフィルを有効成分として含有し、且つ、苦味の隠蔽された高含量速溶フィルム
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
SG10201709195TA (en) 2012-11-13 2017-12-28 Nusirt Sciences Inc Compositions and methods for increasing energy metabolism
KR102146673B1 (ko) 2012-12-04 2020-08-21 주식회사 아리바이오 포스포디에스테라제 타입 ５ 저해제를 포함하는 신경세포의 아폽토시스 억제용 조성물
KR101953735B1 (ko) 2012-12-14 2019-03-04 한미약품 주식회사 포스포다이에스터라제-5 억제제를 포함하는 츄정
MX2015010725A (es) 2013-02-21 2016-05-31 Adverio Pharma Gmbh Formas de metil {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo [3,4-b] piridino-3-il] pirimidino-5-il} metil carbamato.
CA2902879C (en) 2013-03-15 2023-09-26 Nusirt Sciences, Inc. Leucine and nicotinic acid reduces lipid levels
CN106456997B (zh) 2014-02-27 2018-12-28 纽斯尔特科学公司 用于减少或预防肝性脂肪变性的组合物和方法
ES2697902T3 (es) 2014-11-03 2019-01-29 Bayer Pharma AG Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
KR101645652B1 (ko) 2014-11-03 2016-08-08 (주)퓨젠바이오농업회사법인 세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 성기능개선용 조성물
CN104650093B (zh) * 2015-02-02 2017-01-25 王靖林 一种西地那非类似物的合成方法
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
US9988367B2 (en) 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
US10568847B2 (en) * 2016-12-13 2020-02-25 James J. Caprio Compositions and methods for treatment of erectile dysfunction
US11986506B2 (en) 2017-01-20 2024-05-21 Laila Nutraceuticals Dietary supplements for inhibiting PDE5 and increasing cGMP levels
WO2018234506A2 (en) 2017-06-21 2018-12-27 Transgene Sa PERSONALIZED VACCINE
EP3650444B8 (en) * 2017-07-07 2023-10-18 Shanghai Institute of Materia Medica, Chinese Academy of Sciences Salt and polymorph of benzopyrimidinone compound and pharmaceutical composition and use thereof
EP3762020A1 (en) 2018-03-07 2021-01-13 Transgene Parapoxvirus vectors
AU2019287549A1 (en) * 2018-06-14 2021-01-28 Astrazeneca Uk Limited Methods for treating erectile dysfunction with a cgmp-specific phosphodiesterase 5 inhibitor pharmaceutical composition
JP2021527875A (ja) 2018-06-14 2021-10-14 アストラゼネカ・ユーケイ・リミテッドＡｓｔｒａＺｅｎｅｃａ ＵＫ Ｌｉｍｉｔｅｄ Ｃｇｍｐ特異的ホスホジエステラーゼ５阻害剤の薬学的組成物により勃起不全を治療するための方法
SE542968C2 (en) 2018-10-26 2020-09-22 Lindahl Anders Treatment of osteoarthritis
WO2020136235A1 (en) 2018-12-28 2020-07-02 Transgene Sa M2-defective poxvirus
CN113493459B (zh) * 2020-04-07 2022-12-13 广州白云山医药集团股份有限公司白云山制药总厂 Pde5抑制剂化合物及其制备方法和应用
CN111732593A (zh) * 2020-07-07 2020-10-02 黄泳华 哌嗪氧化物衍生物及其组合物、制备方法与用途
CN115785101B (zh) * 2022-11-23 2023-10-13 西安市食品药品检验所 一种含有苯基哌嗪结构的那非类化合物及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1338235A (en) 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
JPS5310599A (en) 1976-07-15 1978-01-31 Harinton Ando Richiyaadoson In Safety device for firearm
FR2547501A1 (fr) 1983-06-15 1984-12-21 Opochimiotherapie Lab Excipient effervescent, sans alcalino-terreux, contenant des composes carbonates de l'arginine et un acide, et comprimes effervescents correspondants
US4521421A (en) * 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
DE3472049D1 (en) 1983-10-31 1988-07-14 Matsushita Electric Ind Co Ltd Optical device and document reader using the same
US4666908A (en) 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
IT1217190B (it) 1988-04-22 1990-03-14 Recordati Chem Pharm Composti utili per il trattamento e diagnosi di disfunzioni frettili
IE61928B1 (en) 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
FR2649613B1 (fr) 1989-07-11 1991-09-27 Virag Ronald Medicament vaso-actif
JPH0344324A (ja) 1989-07-13 1991-02-26 Kazuoki Tsuchiya 性機能賦活剤
AU637873B2 (en) 1990-01-22 1993-06-10 Yamanouchi Pharmaceutical Co., Ltd. A method of treating erectile dysfunction
JP3044324B2 (ja) 1990-02-15 2000-05-22 サカタインクス株式会社 すべり止めニス及びそれを用いたすべり止め加工方法並びにすべり止め加工を施した段ボールの製造方法
US5270323A (en) 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
US5399581A (en) 1990-12-26 1995-03-21 Laragh; John H. Method and compositions for treatment of sexual impotence
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
US5278192A (en) 1992-07-02 1994-01-11 The Research Foundation Of State University Of New York Method of vasodilator therapy for treating a patient with a condition
DE4230755A1 (de) 1992-09-14 1994-03-17 Schering Ag Verwendung von PDE-Inhibitoren bei der Behandlung von Nieren- und Ureter-Erkrankungen
US5891904A (en) 1992-09-14 1999-04-06 Wolf-Georg Forssmann Use of inhibitors of phosphodiesterase IV
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
US5565466A (en) 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
US6037346A (en) 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
EP1027057A4 (en) 1997-10-28 2003-01-02 Vivus Inc TREATMENT OF FEMALE SEXUAL DISORDERS
JP2002543128A (ja) 1999-04-30 2002-12-17 リリー アイコス リミテッド ライアビリティ カンパニー 雌性覚醒障害の処置

Also Published As

Publication number Publication date
FI955911A (fi) 1995-12-08
GR3026520T3 (en) 1998-07-31
RU2373938C9 (ru) 2010-05-27
US6469012B1 (en) 2002-10-22
ES2113656T3 (es) 1998-05-01
NO954757D0 (no) 1995-11-24
PL311948A1 (en) 1996-03-18
KR960702751A (ko) 1996-05-23
CN1071118C (zh) 2001-09-19
NO20000703D0 (no) 2000-02-11
CN1124926A (zh) 1996-06-19
CA2163446C (en) 1998-07-07
JPH11263728A (ja) 1999-09-28
JP2005097304A (ja) 2005-04-14
HU227877B1 (en) 2012-05-29
HU9501933D0 (en) 1995-09-28
CY2099B1 (en) 2002-04-05
KR100262926B1 (ko) 2000-09-01
CN1742731A (zh) 2006-03-08
DE69408981T2 (de) 1998-07-02
MY111446A (en) 2000-05-31
NO20000703L (no) 1995-11-24
CN1742731B (zh) 2012-02-01
NO325558B1 (no) 2008-06-16
NO20000702D0 (no) 2000-02-11
DE69408981D1 (de) 1998-04-16
ECSP941102A (es) 1994-12-15
ZA944018B (en) 1995-12-08
GB9311920D0 (en) 1993-07-28
CZ324295A3 (en) 1996-07-17
EP0702555B1 (en) 1998-03-11
IL109873A (en) 1998-12-27
DK0702555T3 (da) 1998-04-06
CZ284946B6 (cs) 1999-04-14
RU2130776C1 (ru) 1999-05-27
NO321622B1 (no) 2006-06-12
EP0702555A1 (en) 1996-03-27
WO1994028902A1 (en) 1994-12-22
JP2925034B2 (ja) 1999-07-26
NZ314110A (en) 2001-02-23
RU2373938C2 (ru) 2009-11-27
US20030027824A1 (en) 2003-02-06
TW292971B (ru) 1996-12-11
NO20000702L (no) 1995-11-24
GB9301192D0 (en) 1993-06-09
JPH11286444A (ja) 1999-10-19
IL121836A (en) 1998-12-27
AU676571C (en) 2004-01-15
FI955911A0 (fi) 1995-12-08
NZ266463A (en) 1997-03-24
LV12269A (lv) 1999-05-20
IL121836A0 (en) 1998-02-22
JPH09503996A (ja) 1997-04-22
AU676571B2 (en) 1997-03-13
AU6797394A (en) 1995-01-03
IL109873A0 (en) 1994-10-07
LV12269B (en) 1999-08-20
HUT73420A (en) 1996-07-29
ATE163852T1 (de) 1998-03-15
NO309227B1 (no) 2001-01-02
NO954757L (no) 1995-11-24
CA2163446A1 (en) 1994-12-22

Similar Documents

Publication Publication Date Title
NO309227B3 (no) Anvendelse av 5-[2-etoksy-5-(4-metyl-1-piperazinylsulfonyl)fenyl]-1-metyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-on for fremstilling av et medikament for behandling av erektil dysfunksjon
EP0839040B1 (en) Use of cgmp-phosphodiesterase inhibitors to treat impotence
JPH09512835A (ja) 不能症の治療用の二環式複素環式化合物
JP2015517555A (ja) ７−オキソ−チアゾロピリジン炭酸誘導体及びウイルス性疾患の治療、改善又は予防におけるその使用
JP2015521189A (ja) ウイルス性疾患の治療、改善又は予防に有用な７−オキソ−４，７−ジヒドロ−ピラゾロ［１，５−ａ］ピリミジン誘導体
NO20024364L (no) Anvendelse av pyrido [3,2-E]-pyrazinoner som inhibitorer av fosfodiesterase 5 for behandling av erektil dysfunksjon
JP2014530870A (ja) サーチュイン調節因子としての置換された二環式アザ複素環およびアナログ
JP4758993B2 (ja) 末梢動脈疾患の治療に有用であってホスホジエステラーゼ阻害薬として有用なキナゾリン誘導体
CA2262268C (en) Method of treating impotence due to spinal cord injury
JP2002522388A (ja) 性機能障害の治療のためのピリジノン
JP2016504376A (ja) ナフチリジノン誘導体及びウイルス性疾患の治療、改善又は予防におけるそれらの使用
US6465465B1 (en) Process for the treatment of erectile dysfunction and product therefor
DE10104801A1 (de) Pharmazeutische Formulierungen enthaltend Thienopirimidine und Endothelin-Rezeptor-Antagonisten (2)
MXPA01001263A (en) Pyridinones for the treatment of sexual dysfunction

Legal Events

Date Code Title Description
LC4 Limitation of patent rights - b3 (par. 39b patent act)

Effective date: 20110221

MK1K Patent expired